Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Rhea-AI Summary

Immunocore (Nasdaq: IMCR) will present the five-year overall survival (OS) results from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive metastatic uveal melanoma at AACR 2026.

The oral presentation is scheduled for Sunday, 19 April 2026, 3:00–5:00 p.m. PT; a company release will follow with the full five-year OS data and additional analyses including subsequent treatments, treatment beyond progression, and prognostic factors.

Key Figures

Overall survival follow-up: 5-year OS Trial phase: Phase 3 Patient population: HLA-A*02:01 positive +5 more

8 metrics

Overall survival follow-up 5-year OS KIMMTRAK Phase 3 trial in unresected or metastatic uveal melanoma

Trial phase Phase 3 KIMMTRAK (tebentafusp-tebn) trial CT029

Patient population HLA-A*02:01 positive Previously untreated unresected or metastatic uveal melanoma

Conference year 2026 AACR American Association for Cancer Research Annual Meeting

Meeting start date April 17, 2026 AACR Annual Meeting commencement date

Presentation date Sunday 19 April Oral presentation session date

Session time 3:00-5:00 p.m. PT Advanced Cellular and Immune-Based Therapeutics session

Trial identifier CT029 Phase 3 KIMMTRAK survival trial

Market Reality Check

Price: $30.73 Vol: Volume 232,376 vs 20-day ...

low vol

$30.73 Last Close

Volume Volume 232,376 vs 20-day average 394,179 suggests limited pre-news positioning. low

Technical Shares at $30.73, trading below 200-day MA at $34.17 and 24.52% under 52-week high.

Peers on Argus

IMCR fell 0.94% while key biotech peers like SRPT, AUPH, DYN and HRMY rose betwe...

IMCR fell 0.94% while key biotech peers like SRPT, AUPH, DYN and HRMY rose between 0.75% and 3.32%, indicating a stock-specific move rather than a sector rotation.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Investor conferences	Neutral	-0.9%	Planned management presentations at several March 2026 investor conferences.
Feb 25	Earnings and update	Positive	-4.5%	Reported 2025 KIMMTRAK sales, cash position and multiple 2026 data milestones.
Feb 18	Earnings date set	Neutral	+0.4%	Scheduled Q4 and FY 2025 earnings release and conference call details.
Jan 30	R&D leadership change	Neutral	-1.4%	Announced R&D leadership transition and promotions overseeing clinical and regulatory.
Jan 09	Strategic priorities	Positive	-0.1%	Outlined 2026 strategic priorities, Phase 3 timelines and cash position at JPM.

Pattern Detected

Recent positive or strategic updates, including earnings and strategic priorities, often coincided with flat to negative next-day moves, suggesting cautious positioning around news.

Recent Company History

Over the last few months, Immunocore has focused on KIMMTRAK growth and pipeline execution. An 8-K and 10-K on Feb 25, 2026 highlighted 2025 KIMMTRAK sales of $400.0M and ongoing late-stage melanoma programs. Earlier in Jan 2026, management outlined 2026 strategic priorities and R&D leadership changes. The current AACR announcement extends this trajectory, emphasizing long-term survival data for KIMMTRAK in metastatic uveal melanoma after prior guidance on multiple 2026 readouts.

Market Pulse Summary

This announcement highlights upcoming five-year overall survival data from the KIMMTRAK Phase 3 CT02...

Analysis

This announcement highlights upcoming five-year overall survival data from the KIMMTRAK Phase 3 CT029 trial in previously untreated metastatic uveal melanoma at the 2026 AACR meeting. It extends Immunocore’s focus on KIMMTRAK, following prior disclosures of growing sales and multiple Phase 3 programs. Investors may watch the eventual detailed OS release, along with information on subsequent treatments, treatment beyond progression, and prognostic factors, to contextualize KIMMTRAK’s long-term clinical impact.

Key Terms

overall survival, phase 3 trial, HLA-A*02:01, metastatic uveal melanoma, +1 more

5 terms

overall survival medical

"it will present the five-year overall survival (OS) from the KIMMTRAK..."

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

phase 3 trial medical

"in a phase 3 trial (CT029)Presenting author: Paul NathanSession..."

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

HLA-A*02:01 medical

"previously untreated HLA-A*02:01 positive patients with unresected..."

HLA-A*02:01 is a specific genetic variant of the human leukocyte antigen A protein, a display molecule on cells that helps the immune system recognize foreign bits of protein. For investors this matters because many vaccines, cancer immunotherapies, and diagnostic tests work only or best in people with particular HLA types; knowing how common this variant is and whether a therapy targets it affects clinical trial design, patient market size, and commercial prospects.

metastatic uveal melanoma medical

"patients with unresected or metastatic uveal melanoma (mUM), at the 2026..."

Metastatic uveal melanoma is an eye cancer that begins in the uvea (the eye’s middle layer) and has spread to other parts of the body, most often the liver. For investors, it matters because the spread makes the disease much harder to treat, so clinical trial results, regulatory approvals, and new therapies can dramatically change a drug developer’s prospects—think of a small house fire that spreads to the whole neighborhood, changing the value of nearby properties.

prognostic factors medical

"treatment beyond progression, and prognostic factors. Presentation details..."

Prognostic factors are measurable patient characteristics or test results that help predict how a disease will progress or how a patient is likely to respond over time, like age, tumor size, or certain lab markers. For investors, they help gauge the likely commercial and regulatory trajectory of a treatment—similar to how weather signs help you plan a trip—because stronger prognostic indicators can affect trial outcomes, market size estimates, pricing, and risk assessments.

AI-generated analysis. Not financial advice.

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

(OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma (mUM), at the 2026 American Association for Cancer Research (AACR) Annual Meeting commencing on April 17, 2026.

The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond the abstract, the presentation will include additional data such as subsequent treatments in both arms, treatment beyond progression, and prognostic factors.

Presentation details

Title: Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
Presenting author: Paul Nathan
Session: Advanced Cellular and Immune-Based Therapeutics
Date and time: Sunday 19 April – 3:00-5:00 p.m. Pacific Time

###

About ImmTAC^® molecules for cancer

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumors.

About Uveal Melanoma

Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. This is the most common primary intraocular malignancy in adults and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

About KIMMTRAK^®

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s ImmTAC technology platform, designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity

KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).

About KIMMTRAKConnect

Immunocore is committed to helping patients who need KIMMTRAK obtain access via its KIMMTRAKConnect program. The US program provides services with dedicated nurse case managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the timing of the presentation of clinical trial data; the therapeutic potential and expected clinical benefits of KIMMTRAK, including overall survival benefit in patients with unresectable or metastatic uveal melanoma; and expectations regarding the development of Immunocore’s pipeline. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond Immunocore’s control. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 25, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Immunocore’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and Immunocore undertakes no duty to update this information, except as required by law.

Contact Information

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Investor Relations
Morgan Morse
T: +1 (215) 384-4781
E: ir@immunocore.com

FAQ

When will Immunocore (IMCR) present the five-year KIMMTRAK overall survival data at AACR 2026?

Immunocore will present the five-year OS data on Sunday, 19 April 2026, 3:00–5:00 p.m. PT. According to Immunocore, the oral presentation is part of the Advanced Cellular and Immune-Based Therapeutics session and a company release will follow.

What specific data will Immunocore (IMCR) include in the KIMMTRAK AACR 2026 presentation?

The presentation will include the five-year overall survival and additional analyses such as subsequent treatments and prognostic factors. According to Immunocore, it also covers treatment beyond progression and expanded trial analyses beyond the abstract.

Who is presenting the KIMMTRAK five-year survival results for Immunocore (IMCR) at AACR 2026?

The presenting author is Paul Nathan at the AACR session. According to Immunocore, he will present in the Advanced Cellular and Immune-Based Therapeutics session on 19 April 2026.

What patient population is included in the KIMMTRAK five-year OS results presented by Immunocore (IMCR)?

The data cover previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma. According to Immunocore, this is from the Phase 3 randomized CT029 trial and represents the longest OS follow-up in mUM.

Will Immunocore (IMCR) release detailed KIMMTRAK five-year OS results after the AACR presentation?

Yes, Immunocore will issue a company release after the oral presentation containing the full five-year OS data. According to Immunocore, the follow-up release will include additional breakdowns and analyses beyond the oral summary.